A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT
Condition:   Multiple Sclerosis Interventions:   Drug: Alemtuzumab GZ402673;   Drug: Glatiramer acetate;   Drug: Beta-Interferon;   Drug: Methylprednisolone;   Drug: Ranitidine;   Drug: Ceterizine;   Drug: Dexchlorpheniramine;   Drug: Paracetamol;   Drug: Acyclovir;   Drug: Prednisolone Sponsor:   Genzyme, a Sanofi Company Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 11, 2017 Category: Research Source Type: clinical trials